MINERVA SURGICAL INC

2023 Q4 Form 10-Q Financial Statement

#000095017023063069 Filed on November 13, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3 2022 Q3

Balance Sheet

Concept 2023 Q4 2023 Q3 2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $11.10M $15.11M
YoY Change -26.55% 146.61%
Cash & Equivalents $11.13M $15.11M
Short-Term Investments
Other Short-Term Assets $317.0K $119.0K
YoY Change 166.39% -30.0%
Inventory $18.18M $17.00M
Prepaid Expenses $2.402M $1.735M
Receivables $7.569M $6.791M
Other Receivables $0.00 $0.00
Total Short-Term Assets $40.00M $49.20M
YoY Change -18.69% 23.39%
LONG-TERM ASSETS
Property, Plant & Equipment $5.427M $5.031M
YoY Change 7.87% 32.71%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $769.0K $265.0K
YoY Change 190.19% -49.43%
Total Long-Term Assets $32.78M $34.61M
YoY Change -5.28% -16.24%
TOTAL ASSETS
Total Short-Term Assets $40.00M $49.20M
Total Long-Term Assets $32.78M $34.61M
Total Assets $72.79M $83.80M
YoY Change -13.15% 3.22%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.036M $2.822M
YoY Change 7.58% -66.61%
Accrued Expenses $2.366M $10.38M
YoY Change -77.21% -8.73%
Deferred Revenue $202.0K $362.0K
YoY Change -44.2% 38.17%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $11.65M
YoY Change
Total Short-Term Liabilities $21.25M $23.00M
YoY Change -7.58% -65.3%
LONG-TERM LIABILITIES
Long-Term Debt $27.89M $39.27M
YoY Change -28.99% 115.51%
Other Long-Term Liabilities $3.400M $0.00
YoY Change -100.0%
Total Long-Term Liabilities $27.89M $39.27M
YoY Change -28.99% 115.51%
TOTAL LIABILITIES
Total Short-Term Liabilities $21.25M $23.00M
Total Long-Term Liabilities $27.89M $39.27M
Total Liabilities $52.53M $62.27M
YoY Change -15.64% -69.67%
SHAREHOLDERS EQUITY
Retained Earnings -$310.7M -$277.4M
YoY Change 12.0% 6.53%
Common Stock $9.000K $28.00K
YoY Change -67.86% 833.33%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $20.26M $21.54M
YoY Change
Total Liabilities & Shareholders Equity $72.79M $83.80M
YoY Change -13.15% 3.22%

Cashflow Statement

Concept 2023 Q4 2023 Q3 2022 Q3

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Central Index Key
EntityCentralIndexKey
0001452965
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.05
CY2022 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.05
CY2023Q1 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.05
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
CY2023Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.05
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-40919
dei Entity Registrant Name
EntityRegistrantName
MINERVA SURGICAL, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-3422906
dei Entity Address Address Line1
EntityAddressAddressLine1
4255 Burton Dr.
dei Entity Address City Or Town
EntityAddressCityOrTown
Santa Clara
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
95054
dei City Area Code
CityAreaCode
855
dei Local Phone Number
LocalPhoneNumber
646-7874
dei Security12b Title
Security12bTitle
Common Stock, $ 0.001 par value
dei Trading Symbol
TradingSymbol
UTRS
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
8878582
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11125000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6942000
CY2023Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
80000
CY2022Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
604000
CY2023Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
7569000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
7244000
CY2023Q3 us-gaap Inventory Net
InventoryNet
18183000
CY2022Q4 us-gaap Inventory Net
InventoryNet
16850000
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3045000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4479000
CY2023Q3 us-gaap Assets Current
AssetsCurrent
40002000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
36119000
CY2023Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
265000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
265000
CY2023Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
22326000
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
26778000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5427000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5042000
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3996000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
270000
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
769000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
426000
CY2023Q3 us-gaap Assets
Assets
72785000
CY2022Q4 us-gaap Assets
Assets
68900000
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
3036000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2804000
CY2023Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3577000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3701000
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2366000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5524000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
623000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
355000
CY2023Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
11649000
CY2022Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
1894000
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
21251000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
14278000
CY2023Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
27885000
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
37441000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3394000
CY2023Q3 us-gaap Liabilities
Liabilities
52530000
CY2022Q4 us-gaap Liabilities
Liabilities
51719000
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
15000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
8878582
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8878582
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1490761
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1490761
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
9000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
330953000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
300837000
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
11000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
11000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-310718000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-283668000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
20255000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
17181000
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
72785000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
68900000
CY2022 utrs Reduction Of Common Stock
ReductionOfCommonStock
28000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
11965000
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
12588000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
37889000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
36490000
CY2023Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
5747000
CY2022Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
5775000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
17254000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
16619000
CY2023Q3 us-gaap Gross Profit
GrossProfit
6218000
CY2022Q3 us-gaap Gross Profit
GrossProfit
6813000
us-gaap Gross Profit
GrossProfit
20635000
us-gaap Gross Profit
GrossProfit
19871000
CY2023Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
6711000
CY2022Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
9723000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
26274000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
28887000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4190000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6142000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13770000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12706000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1413000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1456000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4655000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3985000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3000
CY2022Q1 utrs Stock Issued During Period Value Vesting Of Early Exercised Stock Options
StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions
39000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1523000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-10925000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
34744000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
18000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
12314000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
17321000
us-gaap Operating Expenses
OperatingExpenses
44699000
us-gaap Operating Expenses
OperatingExpenses
45578000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-6096000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-10508000
us-gaap Operating Income Loss
OperatingIncomeLoss
-24064000
us-gaap Operating Income Loss
OperatingIncomeLoss
-25707000
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
92000
CY2022Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
42000
us-gaap Investment Income Interest
InvestmentIncomeInterest
277000
us-gaap Investment Income Interest
InvestmentIncomeInterest
70000
CY2023Q3 us-gaap Interest Expense
InterestExpense
1172000
CY2022Q3 us-gaap Interest Expense
InterestExpense
861000
us-gaap Interest Expense
InterestExpense
3369000
us-gaap Interest Expense
InterestExpense
2196000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2000
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-7000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-34000
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-7178000
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-11329000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-27163000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-27867000
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
42000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-7181000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-11329000
us-gaap Net Income Loss
NetIncomeLoss
-27205000
us-gaap Net Income Loss
NetIncomeLoss
-27867000
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.81
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.81
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-7.92
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-7.92
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.49
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.49
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-19.48
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-19.48
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8872998
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8872998
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1430056
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1430056
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7805772
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7805772
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1430272
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1430272
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
44104000
CY2022Q2 utrs Stock Issued During Period Value Vesting Of Early Exercised Stock Options
StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions
25000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1676000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-5613000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
30850000
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
13000
CY2022Q3 utrs Stock Issued During Period Value Vesting Of Early Exercised Stock Options
StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions
27000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1977000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-11329000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
21538000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
17181000
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
26774000
CY2023Q1 utrs Stock Issued During Period Value Vesting Of Early Exercised Stock Options
StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions
30000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1274000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-11343000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
34071000
CY2023Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
79000
CY2023Q2 utrs Stock Issued During Period Value Vesting Of Early Exercised Stock Options
StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions
20000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1098000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-8681000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
26587000
CY2023Q3 utrs Stock Issued During Period Value Vesting Of Early Exercised Stock Options
StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions
16000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
833000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-7181000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
20255000
us-gaap Profit Loss
ProfitLoss
-27205000
us-gaap Profit Loss
ProfitLoss
-27867000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
199000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
186000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
92000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
5943000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
8053000
utrs Non Cash Lease Expense
NonCashLeaseExpense
480000
utrs Non Cash Lease Expense
NonCashLeaseExpense
465000
us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
3205000
us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
5176000
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-4094000
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-11000
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-10000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
262000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-501000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
3177000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
3610000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1346000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1874000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
343000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
294000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-807000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-3092000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
90000
us-gaap Increase Decrease In Workers Compensation Liabilities
IncreaseDecreaseInWorkersCompensationLiabilities
-124000
us-gaap Increase Decrease In Workers Compensation Liabilities
IncreaseDecreaseInWorkersCompensationLiabilities
706000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-456000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-606000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-23089000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-19923000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
105000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
125000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-105000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-125000
utrs Proceeds From Issuance Of Common Stock Under Share Purchase Agreement Net
ProceedsFromIssuanceOfCommonStockUnderSharePurchaseAgreementNet
26774000
us-gaap Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
5000000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
34000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
79000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
26853000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-4966000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
3659000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-25014000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
7811000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
48415000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
11470000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
23401000
CY2023Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
11125000
CY2022Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
15112000
CY2023Q3 us-gaap Restricted Cash
RestrictedCash
345000
CY2022Q3 us-gaap Restricted Cash
RestrictedCash
8289000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
11470000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
23401000
us-gaap Interest Paid Net
InterestPaidNet
3141000
us-gaap Interest Paid Net
InterestPaidNet
1930000
us-gaap Income Taxes Paid
IncomeTaxesPaid
42000
utrs Vesting Of Early Exercised Stock Options
VestingOfEarlyExercisedStockOptions
66000
utrs Vesting Of Early Exercised Stock Options
VestingOfEarlyExercisedStockOptions
91000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
6000
utrs Reclassification Of Inventory To Property And Equipment For Customer Usage Agreements
ReclassificationOfInventoryToPropertyAndEquipmentForCustomerUsageAgreements
1844000
utrs Reclassification Of Inventory To Property And Equipment For Customer Usage Agreements
ReclassificationOfInventoryToPropertyAndEquipmentForCustomerUsageAgreements
2289000
utrs Cummulative Effect Adjustment From Adoption Of Credit Losses On Financial Instruments
CummulativeEffectAdjustmentFromAdoptionOfCreditLossesOnFinancialInstruments
155000
utrs Operating Lease Right Of Use Assets Obtained In Exchange For Operating Lease Liabilities
OperatingLeaseRightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilities
4206000
utrs Right Of Use Asset Acquired Under Operating Lease
RightOfUseAssetAcquiredUnderOperatingLease
894000
us-gaap Net Income Loss
NetIncomeLoss
-27200000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-310700000
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11100000
CY2023Q3 utrs Stockholders Equity Reverse Stock Split Effective Date
StockholdersEquityReverseStockSplitEffectiveDate
2023-09-29
CY2023Q3 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
every twenty issued and outstanding shares of common stock was converted into one share of common stock,
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Significant estimates and assumptions include accounts receivable allowances, inventory allowances, recoverability of long-term assets including definite-lived intangible assets, revaluation of equity instruments and equity-linked instruments, stock-based compensation, contingent consideration liability, deferred tax assets and related valuation allowances, impact of contingencies and the Company’s incremental borrowing rate used to calculate lease assets</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentration of credit risk</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially subject the Company to concentrations of risk consist principally of cash, cash equivalents and accounts receivable. The Company maintains its cash and cash equivalents balances with established financial institutions and, at times, such balances with any one financial institution may be in excess of the Federal Deposit Insurance Corporation (FDIC) insured limits. The Company maintains long-term debt with a variable interest rate that resets monthly and has been subject to the recent inflationary rise in interest rates during the past year. Additionally, the Company is subject to interest rate risk when its long-term loan become due and in the event of a refinancing.</span></p><p style="text-indent:0;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company earns revenue from sale of disposable devices and controllers to customers such as hospitals, ambulatory surgical centers and physician offices. The Company’s accounts receivable are derived from revenue earned from customers. The Company performs ongoing credit evaluations of its customers’ financial condition and generally requires no collateral from its customers. At September 30, 2023</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and 2022, and for the periods then ended, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> customer accounted for more than 10.0% of accounts receivable or revenue.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
utrs Number Of Customer Accounted For Accounts Receivable Or Revenue
NumberOfCustomerAccountedForAccountsReceivableOrRevenue
0
utrs Number Of Customer Accounted For Accounts Receivable Or Revenue
NumberOfCustomerAccountedForAccountsReceivableOrRevenue
0
utrs Concentration Of Suppliers
ConcentrationOfSuppliers
<span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentration of suppliers </span><p style="text-indent:0;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company purchases certain components of its products from a single or small number of suppliers. A change in or loss of these suppliers could cause a delay in filling customer orders and a possible loss of sales, which could adversely affect our results of operations; however, management believes that suitable replacement suppliers could be obtained in such an event.</span></p>
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
542000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
92000
us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
40000
CY2023Q3 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
594000
CY2023Q3 us-gaap Advertising Expense
AdvertisingExpense
0
us-gaap Advertising Expense
AdvertisingExpense
100000
CY2022Q3 us-gaap Advertising Expense
AdvertisingExpense
200000
us-gaap Advertising Expense
AdvertisingExpense
400000
CY2023Q3 utrs Percentage Of Revenue From Contract With Customer Excluding Assessed Tax
PercentageOfRevenueFromContractWithCustomerExcludingAssessedTax
1
CY2022Q2 utrs Percentage Of Revenue From Contract With Customer Excluding Assessed Tax
PercentageOfRevenueFromContractWithCustomerExcludingAssessedTax
1
utrs Percentage Of Revenue From Contract With Customer Excluding Assessed Tax
PercentageOfRevenueFromContractWithCustomerExcludingAssessedTax
1
utrs Percentage Of Revenue From Contract With Customer Excluding Assessed Tax
PercentageOfRevenueFromContractWithCustomerExcludingAssessedTax
1
CY2023Q3 utrs Percentage Of Revenue Subject To Point In Time Recognition
PercentageOfRevenueSubjectToPointInTimeRecognition
0.999
CY2022Q3 utrs Percentage Of Revenue Subject To Point In Time Recognition
PercentageOfRevenueSubjectToPointInTimeRecognition
0.999
CY2023Q3 utrs Percentage Of Revenue On Sale Of Extended Warranties On Capital Equipment
PercentageOfRevenueOnSaleOfExtendedWarrantiesOnCapitalEquipment
0.001
CY2022Q3 utrs Percentage Of Revenue On Sale Of Extended Warranties On Capital Equipment
PercentageOfRevenueOnSaleOfExtendedWarrantiesOnCapitalEquipment
0.001
CY2023Q3 utrs Percentage Of Total Revenue Derived From Sale Of Single Use Disposable Products
PercentageOfTotalRevenueDerivedFromSaleOfSingleUseDisposableProducts
0.987
CY2022Q3 utrs Percentage Of Total Revenue Derived From Sale Of Single Use Disposable Products
PercentageOfTotalRevenueDerivedFromSaleOfSingleUseDisposableProducts
0.97
utrs Percentage Of Revenue Subject To Point In Time Recognition
PercentageOfRevenueSubjectToPointInTimeRecognition
0.999
utrs Percentage Of Revenue Subject To Point In Time Recognition
PercentageOfRevenueSubjectToPointInTimeRecognition
0.999
utrs Percentage Of Revenue On Sale Of Extended Warranties On Capital Equipment
PercentageOfRevenueOnSaleOfExtendedWarrantiesOnCapitalEquipment
0.001
utrs Percentage Of Revenue On Sale Of Extended Warranties On Capital Equipment
PercentageOfRevenueOnSaleOfExtendedWarrantiesOnCapitalEquipment
0.001
utrs Percentage Of Total Revenue Derived From Sale Of Single Use Disposable Products
PercentageOfTotalRevenueDerivedFromSaleOfSingleUseDisposableProducts
0.985
utrs Percentage Of Total Revenue Derived From Sale Of Single Use Disposable Products
PercentageOfTotalRevenueDerivedFromSaleOfSingleUseDisposableProducts
0.98
CY2023Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
7569000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
7244000
CY2023Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
202000
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
339000
CY2023Q3 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
9077000
CY2023Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
9077000
CY2022Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
3149000
CY2022Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
3149000
CY2021Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
14094000
CY2022Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
-151000
CY2022Q1 utrs Payments
Payments
-5000000
CY2022Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
8943000
CY2022Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
-3943000
CY2022Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
5000000
CY2022Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
0
CY2022Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
5000000
CY2023Q3 us-gaap Cash
Cash
2048000
CY2022Q4 us-gaap Cash
Cash
3793000
CY2023Q3 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
9077000
CY2022Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
3149000
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11125000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6942000
CY2023Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
8845000
CY2022Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
7142000
CY2023Q3 utrs Inventory Component Materials
InventoryComponentMaterials
9338000
CY2022Q4 utrs Inventory Component Materials
InventoryComponentMaterials
9708000
CY2023Q3 us-gaap Inventory Net
InventoryNet
18183000
CY2022Q4 us-gaap Inventory Net
InventoryNet
16850000
CY2023Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
2402000
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
2164000
CY2023Q3 us-gaap Prepaid Insurance
PrepaidInsurance
326000
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
1560000
CY2023Q3 us-gaap Other Assets Current
OtherAssetsCurrent
317000
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
755000
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3045000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4479000
CY2023Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
16506000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
15467000
CY2023Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
11079000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
10425000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5427000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5042000
CY2023Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
500000
CY2022Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
600000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1500000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1900000
CY2023Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
48254000
CY2023Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
25928000
CY2023Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
22326000
CY2022Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
48254000
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
21476000
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
26778000
CY2023Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
900000
CY2022Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2000000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
4500000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
6100000
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
923000
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
3693000
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
3693000
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
3614000
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
3082000
CY2023Q3 utrs Finite Lived Intangible Asset Expected Amortization After Year Four
FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour
7321000
CY2023Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
22326000
CY2023Q3 us-gaap Accrued Vacation Current
AccruedVacationCurrent
1391000
CY2022Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
1559000
CY2023Q3 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
1745000
CY2022Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
1248000
CY2023Q3 us-gaap Accrued Sales Commission Current
AccruedSalesCommissionCurrent
337000
CY2022Q4 us-gaap Accrued Sales Commission Current
AccruedSalesCommissionCurrent
730000
CY2023Q3 us-gaap Other Employee Related Liabilities Current
OtherEmployeeRelatedLiabilitiesCurrent
104000
CY2022Q4 us-gaap Other Employee Related Liabilities Current
OtherEmployeeRelatedLiabilitiesCurrent
164000
CY2023Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3577000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3701000
CY2022Q4 utrs Accrued Litigation
AccruedLitigation
2000000
CY2023Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
240000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
643000
CY2023Q3 utrs Accrued Sales And Use Taxes
AccruedSalesAndUseTaxes
121000
CY2022Q4 utrs Accrued Sales And Use Taxes
AccruedSalesAndUseTaxes
271000
CY2023Q3 utrs Accrual For Inventory In Transit
AccrualForInventoryInTransit
475000
CY2022Q4 utrs Accrual For Inventory In Transit
AccrualForInventoryInTransit
663000
CY2023Q3 utrs Accrued Contract Liability
AccruedContractLiability
202000
CY2022Q4 utrs Accrued Contract Liability
AccruedContractLiability
339000
CY2023Q3 us-gaap Interest Payable Current
InterestPayableCurrent
350000
CY2022Q4 us-gaap Interest Payable Current
InterestPayableCurrent
321000
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
978000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1287000
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2366000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5524000
CY2023Q3 us-gaap Other Inventory In Transit
OtherInventoryInTransit
200000
CY2023Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
281000
CY2022Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
163000
us-gaap Operating Lease Cost
OperatingLeaseCost
647000
us-gaap Operating Lease Cost
OperatingLeaseCost
490000
CY2023Q3 us-gaap Variable Lease Cost
VariableLeaseCost
40000
CY2022Q3 us-gaap Variable Lease Cost
VariableLeaseCost
38000
us-gaap Variable Lease Cost
VariableLeaseCost
203000
us-gaap Variable Lease Cost
VariableLeaseCost
186000
CY2023Q3 us-gaap Lease Cost
LeaseCost
321000
CY2022Q3 us-gaap Lease Cost
LeaseCost
201000
us-gaap Lease Cost
LeaseCost
850000
us-gaap Lease Cost
LeaseCost
676000
CY2023Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
265000
CY2022Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
214000
us-gaap Operating Lease Payments
OperatingLeasePayments
709000
us-gaap Operating Lease Payments
OperatingLeasePayments
631000
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
894000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
4206000
CY2023Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.1225
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.04
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y8M12D
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P0Y4M24D
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4000000.0
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
4000000
CY2023Q3 us-gaap Finance Lease Liability
FinanceLeaseLiability
0
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
353000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1081000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1114000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1147000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1182000
CY2023Q3 utrs Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
398000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
5275000
CY2023Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
1258000
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
4017000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
623000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3394000
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
42000
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
15000000
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2017Q2 utrs Class Of Warrant Or Right To Purchase Of Common Stock Issuance Date
ClassOfWarrantOrRightToPurchaseOfCommonStockIssuanceDate
2017-05-09
CY2017Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
1696
CY2017Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
226.2
CY2017Q2 utrs Class Of Warrant Or Right Classification
ClassOfWarrantOrRightClassification
Equity
CY2017Q2 us-gaap Warrants And Rights Outstanding Maturity Date
WarrantsAndRightsOutstandingMaturityDate
2027-05-08
CY2019Q3 utrs Class Of Warrant Or Right To Purchase Of Common Stock Issuance Date
ClassOfWarrantOrRightToPurchaseOfCommonStockIssuanceDate
2019-07-19
CY2019Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2192
CY2019Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
226.2
CY2019Q3 utrs Class Of Warrant Or Right Classification
ClassOfWarrantOrRightClassification
Equity
CY2019Q3 us-gaap Warrants And Rights Outstanding Maturity Date
WarrantsAndRightsOutstandingMaturityDate
2029-07-18
CY2023Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
3888
CY2023Q2 utrs Warrants To Purchase Common Stock
WarrantsToPurchaseCommonStock
3888
CY2022Q4 utrs Warrants To Purchase Common Stock
WarrantsToPurchaseCommonStock
3888
CY2023Q2 utrs Common Stock Options Issued And Outstanding
CommonStockOptionsIssuedAndOutstanding
1310122
CY2022Q4 utrs Common Stock Options Issued And Outstanding
CommonStockOptionsIssuedAndOutstanding
114530
CY2023Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
724243
CY2022Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
18705
CY2023Q2 utrs Restricted Stock Units Issued And Outstanding
RestrictedStockUnitsIssuedAndOutstanding
24782
CY2022Q4 utrs Restricted Stock Units Issued And Outstanding
RestrictedStockUnitsIssuedAndOutstanding
62353
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
114357
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
166.72
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1271964
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
5.58
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
1591
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
6.53
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
74608
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
48.96
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1310122
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y2M12D
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
182188
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
79.83
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y10M24D
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
1310122
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
17.18
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P9Y2M12D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
2600000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
2900000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.96
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
42.29
CY2023Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
6300000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y1M6D
CY2023Q3 utrs Repurchase Of Common Stock
RepurchaseOfCommonStock
0
utrs Repurchase Of Common Stock
RepurchaseOfCommonStock
0
CY2022Q3 utrs Repurchase Of Common Stock
RepurchaseOfCommonStock
0
utrs Repurchase Of Common Stock
RepurchaseOfCommonStock
0
CY2023Q3 utrs Shares Subject To Repurchase
SharesSubjectToRepurchase
4761
CY2022Q4 utrs Shares Subject To Repurchase
SharesSubjectToRepurchase
9401
CY2023Q3 utrs Share Based Compensation Arrangements By Share Based Payment Award Options Aggregate Amounts Of Not Yet Vested Early Stock
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAggregateAmountsOfNotYetVestedEarlyStock
100000
CY2022Q4 utrs Share Based Compensation Arrangements By Share Based Payment Award Options Aggregate Amounts Of Not Yet Vested Early Stock
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAggregateAmountsOfNotYetVestedEarlyStock
100000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
833000
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1977000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3205000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5176000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
833000
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1977000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3205000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5176000
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.781
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.722
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.774
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.781
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.708
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.722
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.04
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.028
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.042
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.019
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.03
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-7181000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-11329000
us-gaap Net Income Loss
NetIncomeLoss
-27205000
us-gaap Net Income Loss
NetIncomeLoss
-27867000
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8872998
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8872998
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1430056
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1430056
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7805772
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7805772
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1430272
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1430272
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.81
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.81
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-7.92
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-7.92
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.49
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.49
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-19.48
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-19.48

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
utrs-20230930_cal.xml Edgar Link unprocessable
utrs-20230930_pre.xml Edgar Link unprocessable
0000950170-23-063069-index-headers.html Edgar Link pending
0000950170-23-063069-index.html Edgar Link pending
0000950170-23-063069.txt Edgar Link pending
0000950170-23-063069-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
utrs-20230930.htm Edgar Link pending
utrs-20230930.xsd Edgar Link pending
utrs-ex31_1.htm Edgar Link pending
utrs-ex31_2.htm Edgar Link pending
utrs-ex32_1.htm Edgar Link pending
utrs-ex32_2.htm Edgar Link pending
utrs-ex3_1.htm Edgar Link pending
utrs-20230930_lab.xml Edgar Link unprocessable
utrs-20230930_def.xml Edgar Link unprocessable
utrs-20230930_htm.xml Edgar Link completed